Form 8-K
8-K — INTEGRA LIFESCIENCES HOLDINGS CORP
Accession: 0000917520-26-000067
Filed: 2026-10-02
Period: 2026-10-02
CIK: 0000917520
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Results of Operations and Financial Condition
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — iart-20261002.htm (Primary)
EX-99.1 (ex991_q3pressreleasepreann.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: iart-20261002.htm · Sequence: 1
iart-20261002
0000917520false00009175202026-10-022026-10-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2026
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-26224 51-0317849
(State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
1100 Campus Road
Princeton, NJ 08540
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities Registered Pursuant to Section12(b) of the Act:
Title of Each Class Trading Symbol Name of Exchange on Which Registered
Common Stock, Par Value $.01 Per Share IART Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 Results of Operations and Financial Condition.
Preliminary Unaudited Results for the Third Quarter
On October 2, 2026, Integra LifeSciences Holdings Corporation (the “Company”) announced certain preliminary unaudited results for the third quarter ended September 30, 2026. The Company expects its reported revenue to be between $410 million to $412 million, reflecting an estimated $7 million impact of flooding-related supply disruptions on the Company’s manufacturing facility in Cincinnati, Ohio (the “Cincinnati facility”). The Company expects its adjusted earnings per diluted share for the third quarter to be between $0.55 to $0.59. In addition, the Company expects operating cashflow to be greater than $85 million in the third quarter.
The preliminary financial information set forth above is unaudited and based on currently available information. It remains subject to completion of the Company’s financial closing procedures, and is not a comprehensive statement of the Company’s financial results for the period. This information does not present all information necessary for a complete understanding of the Company’s results of operations for the period and has not been reviewed by the Company’s independent registered public accounting firm.
ITEM 7.01 Regulation FD Disclosure.
On October 2, 2026, the Company issued a press release that announced certain preliminary unaudited results for the third quarter ended September 30, 2026 and provided an update on the Company’s Cincinnati facility. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release, dated October 2, 2026, issued by Integra LifeSciences Holdings Corporation.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Non-GAAP Financial Measures
This Current Report on Form 8-K references adjusted earnings per diluted share which is a financial measure that is not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Adjusted earnings per diluted share is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. Adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility (the “Braintree transition”); (v) intangible asset amortization expense; (vi) income tax impact from adjustments; and (vii) impairment charges. The Company believes that the presentation of the adjusted earnings per diluted share measure provides important supplemental information to management and investors regarding financial and business trends relating to the Company’s financial condition and results of operations. Such non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP and should be reviewed in conjunction with the Company’s consolidated financial statements and publicly filed reports in their entirety.
The Company provided the foregoing unaudited, preliminary third quarter results regarding adjusted earnings per diluted share but has not provided a reconciliation of GAAP earnings per share to adjusted earnings per diluted share, because certain GAAP expense items are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort at this time.
Cautionary Note Regarding Forward-Looking Statements
The Current Report on Form 8-K forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to: our preliminary unaudited results for the third quarter ended September 30, 2026; the preliminary estimated impact of flooding-related supply disruptions at the Cincinnati facility, including on revenue, adjusted earnings per diluted share and our financial condition and results of operations more generally; our fiscal 2026 guidance and our ability to deliver on such financial guidance; our expectations and progress in our recovery efforts, including timing and costs; and expected insurance coverage and recoveries. Forward-looking statements in this Current Report on Form 8-K should be evaluated together with the many risks and uncertainties that affect the Company’s business and market, including: our ongoing assessment of the flooding event at the Cincinnati facility, related financial impacts, recovery efforts, potential asset impairments, unforeseen costs and insurance recoveries; and other risks identified under the heading “Risk Factors” included in item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: October 2, 2026 By: /s/ Lea Knight
Lea Knight
Title:
Executive Vice President and Chief Financial Officer
EX-99.1
EX-99.1
Filename: ex991_q3pressreleasepreann.htm · Sequence: 2
Document
Integra LifeSciences
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
PRINCETON, N.J., October 2, 2026 – Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.
“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.”
Mr. Essig continued, “While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”
Update on Cincinnati Facility
As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed on the second quarter earnings call, flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption to the site. The facility manufactures and supports several products within the Company's Specialty Surgical Technologies portfolio.
Since the event, Integra has continued to execute its business continuity and recovery plans. The Company has utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility. These actions are intended to support customers and mitigate disruption while recovery efforts continue.
Based on its current assessment, Integra estimates that the flooding related supply disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million. The Company expects a return to full manufacturing operations at the site during the second quarter of 2027.
Integra maintains property and business interruption insurance covering the Cincinnati facility. Based on its current assessment, the Company expects insurance recoveries to mitigate a
1
substantial portion of the earnings impact associated with the disruption throughout the recovery period and until the facility returns to full manufacturing capacity. The Company continues to work with its insurance carrier to assess and document recoverable losses associated with the event, including both property damage and business interruption claims.
Preliminary Third Quarter Results and Updated Full-Year Guidance
For the third quarter of 2026, the Company expects to report revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. The preliminary results as set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures.
For the full year 2026, the Company is updating its reported revenue outlook from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion. The Company is updating its adjusted earnings per diluted share guidance from a range of $2.40 to $2.50 to a range of $2.30 to $2.40 and expects operating cash flow for the year to be approximately $190 million to $200 million.
The third quarter preliminary results and updated full-year guidance reflect revised assumptions regarding the expected impact of the July flooding event at the Cincinnati facility, as well as updated assumptions for the broader business for the remainder of the year.
The Company will report its third quarter 2026 financial results during a conference call in October 2026. A press release with the date, time and webcast information will be provided closer to the reporting date. The Company will provide additional information regarding its third quarter financial results and outlook for full-year 2026 at that time.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to: our preliminary unaudited results for the third quarter ended September 30, 2026; the preliminary estimated impact of the flooding event at our Cincinnati, Ohio manufacturing facility (the “Cincinnati facility”), including
2
on revenue, adjusted earnings per diluted share and our financial condition and results of operations more generally; our fiscal 2026 guidance and our ability to deliver on such financial guidance; our expectations and progress in our recovery efforts, including timing and costs; and expected insurance coverage and recoveries. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra’s business and market, including: our ongoing assessment of the flooding event at the Cincinnati facility, related financial impacts, recovery efforts, potential asset impairments, unforeseen costs and insurance recoveries; and other risks identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. These forward-looking statements are made only as the date thereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
3
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Document and Entity Information
Oct. 02, 2026
Entity Information [Line Items]
Document Type
8-K
Document Period End Date
Oct. 02, 2026
Entity Registrant Name
INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Incorporation, State or Country Code
DE
Entity File Number
0-26224
Entity Tax Identification Number
51-0317849
Entity Address, Address Line One
1100 Campus Road
Entity Address, City or Town
Princeton
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
08540
City Area Code
609
Local Phone Number
275-0500
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, Par Value $.01 Per Share
Trading Symbol
IART
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
Entity Central Index Key
0000917520
Amendment Flag
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details
Name:
dei_EntityInformationLineItems
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration